Pasithea Therapeutics Corp (NASDAQ:KTTA) currently has a daily average trading volume of 1.10M but it saw 101146013 shares traded in last market. With a market cap of 4.33M USD, the company’s current market price of $1.60 came rising about 46.79 while comparing to the previous closing price of $1.09. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.25 and as low as $0.92. In the recent trading on the day, stock has struck highest price mark of $1.42 while lowest mark touched by it was $2.34.
Taking a look at 20-day trading activity of Pasithea Therapeutics Corp (KTTA) gives us an average price of $1.2400, while its current price level is -80.61% below from 52-week high level whereas it is 73.42% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.3828 while that of 200 days or SMA-200 reads an average of $3.3966. A closer look into the stock’s movement over the week reveals that its volatility is standing at 19.36% during that period while stretching the period over a month that decreases to 11.70%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 62.91 which implies that the stock is in neutral territory.
Over the week, KTTA’s stock price is moving 25.98% up while it is 55.34% when we observe its performance for the past one month. Year-to-date it is -49.21% down and over the past year, the stock is showing a downside performance of -77.62%.
The company is expected to be releasing its next quarterly report on 2022-May-15, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Pasithea Therapeutics Corp’s total number of outstanding shares is 2.71M with 8.93% of that held by the insiders while 4.65% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -94.06% and return on equity (ROE) at -72.83%. Stock’s beta reads 0.62. Stock has a price to book (P/B) ratio of 0.15. Its return on asset (ROA) is -65.93% on average.
